STOCK TITAN

Health In Tech swings to $7.07M Q3 2026 net loss

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Health In Tech, Inc. reported third-quarter 2026 revenue of $6,587,052, versus $8,490,093 in the quarter ended September 30, 2025, and a net loss attributable to common stockholders of $7,066,413, versus $452,176 of income. Adjusted EBITDA was a loss of $3,932,017, compared with $999,056 of positive Adjusted EBITDA. For the first nine months of 2026, revenue was $23,415,318 versus $25,818,926, and net loss attributable to common stockholders was $11,165,718 versus $1,581,399 of income.

The company reported $32.7 million in contracted revenue for the first nine months and $91.8 million in Platform Placed Plan Value as of September 30, 2026. Its pipeline represented approximately $156.4 million in potential annualized revenue as of October 30, 2026; distribution partners grew 15.9% year over year. CEO Sanjay Shrestha identified improving quote-to-bind conversion and translating marketplace activity into placed policies and recognized revenue as immediate priorities. The company expects to provide a fuller update on strategic priorities with its full-year 2026 results.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 5 points

How the balance works

Positive

  • None.

Negative

  • Major pointThird-quarter net loss attributable to common stockholders was $7,066,413, versus $452,176 of income.
  • Moderate pointThird-quarter revenue was $6,587,052, versus $8,490,093 in 2025.
  • Moderate pointAdjusted EBITDA was a $3,932,017 loss, versus $999,056 positive in 2025.
  • Minor pointNine-month revenue was $23,415,318, versus $25,818,926 in 2025.
  • Minor pointNine-month net loss attributable to common stockholders was $11,165,718, versus $1,581,399 of income.

Filing Explained

The quarter-end balance sheet reports $10,127,237 cash and $6,639,108 in convertible notes payable; for the first nine months, operating activities used $7,277,043, while note issuance provided $6,650,000 in financing cash.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter revenue $6,587,052 Three months ended September 30, 2026; $8,490,093 in the three months ended September 30, 2025.
Third-quarter net loss attributable to common stockholders $7,066,413 loss Three months ended September 30, 2026; $452,176 income in the three months ended September 30, 2025.
Third-quarter Adjusted EBITDA $3,932,017 loss Three months ended September 30, 2026; $999,056 positive in the three months ended September 30, 2025.
Nine-month revenue $23,415,318 Nine months ended September 30, 2026; $25,818,926 in the nine months ended September 30, 2025.
Nine-month net loss attributable to common stockholders $11,165,718 loss Nine months ended September 30, 2026; $1,581,399 income in the nine months ended September 30, 2025.
Contracted revenue $32.7 million First nine months of 2026.
Platform Placed Plan Value $91.8 million As of September 30, 2026.
Pipeline revenue Approximately $156.4 million Potential annualized revenue as of October 30, 2026.
Adjusted EBITDA financial
"Adjusted EBITDA should not be considered an alternative to net income"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Contracted Revenue financial
"we had $32.7 million Contracted Revenue"
Contracted revenue is the amount of money a business expects to receive because customers have signed binding agreements for goods or services over a set period. For investors it shows how much future cash is already promised, reducing uncertainty about sales — like having customers hand you a schedule of payments in advance — which helps assess growth potential, valuation and risk compared with one-off or uncertain sales.
Platform Placed Plan Value financial
"$91.8 million in Platform Placed Plan Value"
quote-to-bind conversion technical
"improve quote-to-bind conversion"
self-funded health plans technical
"customized self-funded health plans"
A self-funded health plan is when an employer pays employee medical claims out of its own funds instead of buying a traditional insurance policy; the employer may hire administrators or buy stop‑loss coverage to manage large or unpredictable claims. Investors care because these plans shift health‑care cost risk onto the employer, affecting its cash flow, balance‑sheet volatility and future expense predictability—similar to opting to pay for repairs yourself rather than buying a fixed warranty.
bindable stop-loss quotes technical
"bindable stop-loss quotes"
Third-quarter revenue $6,587,052 Down from $8,490,093 in the third quarter of 2025
Third-quarter net loss attributable to common stockholders $7,066,413 loss Versus net income of $452,176 in the third quarter of 2025
Third-quarter Adjusted EBITDA $3,932,017 loss Versus $999,056 positive in the third quarter of 2025
Nine-month revenue $23,415,318 Down from $25,818,926 in the first nine months of 2025
Nine-month net loss attributable to common stockholders $11,165,718 loss Versus net income of $1,581,399 in the first nine months of 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were HIT's third-quarter 2026 revenue and net loss?

Health In Tech reported third-quarter revenue of $6,587,052 and a net loss attributable to common stockholders of $7,066,413. In the quarter ended September 30, 2025, revenue was $8,490,093 and net income attributable to common stockholders was $452,176.

What was HIT's pipeline revenue as of October 30, 2026?

Health In Tech described its pipeline as approximately $156.4 million in potential annualized revenue as of October 30, 2026. It also reported $32.7 million in contracted revenue for the first nine months of 2026 and $91.8 million in Platform Placed Plan Value as of September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0002019505 0002019505 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

November 12, 2026

Date of Report (Date of earliest event reported)

 

Health In Tech, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-42449   87-3545722
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

701 S. Colorado Ave, Suite 1

Stuart, FL

  34994
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 373-0333

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, $0.001 par value per share   HIT  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 12, 2026, Health In Tech, Inc., a Nevada corporation (the “Company”) issued a press release announcing its results of operations for the quarter ended September 30, 2026, attached hereto as Exhibit 99.1.

 

Item 7.01. Regulation FD Disclosure.

 

As disclosed in Item 2.02 above, on November 12, 2026, the Company issued a press release announcing its results of operations for the quarter ended September 30, 2026, attached hereto as Exhibit 99.1. The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

 

Forward-Looking Statements

 

Certain statements in this Current Report on Form 8-K or in the accompanying exhibits are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” “objective,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause the Company’s actual results to differ materially from those presented in its forward-looking statements are set forth in the “Risk Factors” section in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in the Company’s subsequent reports. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity. Health In Tech undertakes no obligation to update any forward-looking statements, except as required by law.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
99.1   Press release dated November 12, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 13, 2026

 

HEALTH IN TECH, INC.

 

By: /s/ Sanjay Shrestha  
Name:  Sanjay Shrestha  
Title: Chief Executive Officer  

 

2

 

Exhibit 99.1

 

Health In Tech Reports Third Quarter 2026 Financial Results

Contracted Revenue of $32.7 Million for the First Nine Months of 2026
Pipeline Revenue of $156.4 Million as of October 30, 2026
Distribution Partners Grew 15.9% Year Over Year

 

Stuart, FL., November 12, 2026 /PRNewswire/ — Health In Tech, Inc. (Nasdaq: HIT) (“Health In Tech” or the “Company”), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the third quarter ended September 30, 2026.

 

Third Quarter and Nine-Month 2026 Highlights

 

●Distribution Partners, including brokers, third-party administrators (“TPAs”) and agencies, reached 984 as of September 30, 2026, an increase of 15.9% year over year.

 

●Q3 2026 Revenue was $6.6 million, compared with $8.5 million in Q3 2025. Nine-month 2026 revenue was $23.4 million, compared with $25.8 million in the prior year period.

 

●Contracted Revenue1 totaled $32.7 million for the first nine months of 2026, of which $24.4 million was recognized as GAAP revenue, before the enrollment adjustment and refund liability. The remaining $6.1 million and $2.2 million are expected to be recognized as GAAP revenue in the fourth quarter of 2026 and in 2027, respectively.

 

●Pipeline Revenue2 as of October 30, 2026 was $156.4 million, of which $2.6 million was contracted subsequent to quarter end. The remaining $153.8 million represents policies in quoting or binding status, with an expected conversion rate of 3% to 7%.

 

●Net Loss for Q3 2026 was $7.1 million, or $(0.11) per diluted share, and included a provision for credit losses of $5.3 million, compared to net income of $0.5 million, or $0.01 per diluted share, in Q3 2025. Net loss for the first nine months of 2026 was $11.2 million, or $(0.18) per diluted share, and included a provision for credit losses of $6.1 million, compared to net income of $1.6 million, or $0.03 per diluted share, for the first nine months of 2025.

 

●Adjusted EBITDA3 was $(3.9) million for Q3 2026 and $(6.6) million for the first nine months of 2026, reflecting continued investment in distribution, technology, and product development.

 

●Platform Placed Plan Value (“PPPV”)4 was $91.8 million as of September 30, 2026.

 

●Cash balance was $10.1 million as of September 30, 2026.

 

CEO Commentary

 

Sanjay Shrestha, Chief Executive Officer of Health In Tech, commented:

 

“It is a privilege to lead Health In Tech into its next chapter, and I want to thank Tim Johnson, our founder and Executive Chairman, and the Board for their confidence. Throughout my career, I have focused on scaling businesses, developing growth strategies, and leveraging capital markets to support long-term value creation. I have substantial operational experience scaling new products from incubation to meaningful commercial scale, building large scale process plants, and renewable assets on global basis. These experiences reinforce the importance of aligning commercial execution, operational discipline, and capital allocation. Having previously served as a director on Health In Tech’s Board and then as a strategic advisor to the Board, I have gained valuable perspective on the Company’s technology foundation, business model, and market opportunities. I look forward to bringing my experience and a fresh perspective to help unlock the next phase of growth.

 

 

 

Health In Tech has established a strong technology foundation and a substantial pipeline of commercial opportunities. For the first nine months 2026, we had $32.7 million Contracted Revenue and as of September 30, 2026, we had achieved $91.8 million in Platform Placed Plan Value. As of October 30, 2026, our pipeline represented approximately $156.4 million in potential annualized revenue, which we refer to as pipeline revenue. These metrics illustrate the scale of activity across our marketplace and the opportunities ahead. However, we recognize that our reported financial performance has not yet fully reflected the potential of our platform. Our immediate priority is to improve quote-to-bind conversion, translate marketplace activity into placed policies and recognized revenue, and strengthen overall financial performance.

 

During 2026, the Company has invested in expanding its distribution network, strengthening carrier and strategic partnerships, and advancing new technology and products. Our existing eDIYBS and SMR platforms, together with HitRix, HitChain and the Three-Year Rate Stabilization Program, provide multiple avenues for future growth. As we move into 2027, our focus will increasingly shift toward commercialization, disciplined execution, and generating measurable returns from these investments.

 

Since assuming the CEO role, I have initiated a comprehensive review of our commercial operations, organizational capabilities, cost structure, and capital allocation priorities. We are focused on strengthening commercial execution, improving operating efficiency, and scaling our existing businesses. At the same time, we will evaluate strategic acquisitions, partnerships, and other expansion opportunities that could complement our platform, accelerate growth, and enhance long-term shareholder value. We expect to provide a more detailed update on our strategic priorities when we report our full-year 2026 results.

 

With Tim continuing to lead long-term strategy, technology innovation, and product development as Executive Chairman, we have an opportunity to combine his deep insurance industry expertise and entrepreneurial vision with my experience in business scaling, capital markets, and strategic execution. Our objective is to transform the strong foundation we believe Health In Tech has built into a more scalable, commercially successful, and financially disciplined business that creates sustainable long-term shareholder value.”

 

Corporate and Strategic Highlights

 

●HitRix Launch. Launched HitRix in September 2026, an AI-powered, broker-first marketplace designed to modernize the large-group self-funded stop-loss insurance placement process. By automating data ingestion, streamlining submissions across multiple carriers and managing general underwriters (“MGUs”), and enabling more efficient proposal comparisons, HitRix aims to reduce manual workflows, enhance broker productivity, improve quoting efficiency, and drive higher policy placement conversion rates.

 

2

 

 

●Three-Year Rate Stabilization Program. The Company continues to advance its Three-Year Rate Stabilization Program, designed to provide employers with greater predictability in stop-loss insurance costs over a multi-year period. The Company has secured its first client. With the initial launch targeted by year-end 2026, the Company is prioritizing disciplined execution and aims to establish a foundation for converting its pipeline into future commercial growth.

 

●Strategic Leadership Transition. Appointed Sanjay Shrestha as Chief Executive Officer, effective October 20, 2026, to lead commercial execution, business expansion, and strategic growth. Mr. Shrestha brings extensive experience in public-company leadership, capital markets, and strategic acquisitions, as well as an established understanding of Health In Tech through both his prior service as a member of our Board and, later, as a strategic advisor to our Board. Founder Tim Johnson transitioned to Executive Chairman to focus on long-term strategy, technology innovation, and product development.

 

●Strengthened Board Expertise. Elected Tim Cortes as an independent director at the Company’s November 10, 2026 Annual Meeting of Stockholders, bringing extensive technology and engineering leadership experience to our Board.

 

●Updated 2026 Revenue Outlook. The Company revised its full-year 2026 revenue outlook to approximately $30 million, modestly below 2025 revenue. The revision primarily reflects the delayed commencement of certain new policies resulting from the transition to a new carrier, which temporarily extended underwriting and onboarding timelines. These delays shifted the anticipated revenue contribution from certain new business opportunities into 2027, rather than reflecting a loss of the underlying opportunities. With the carrier transition substantially completed, the Company is focused on accelerating policy onboarding, improving conversion rates, and translating its existing pipeline into revenue growth in 2027.

 

End Notes

 

1.Contracted Revenue is a period-based operating metric and is not a point-in-time backlog measure. Contracted Revenue includes contractual revenue associated with policies that are in force at any time during the applicable reporting period. For each such policy, Contracted Revenue includes: contractual revenue attributable to the portion of the policy term falling within the reporting period, including the amount recognized as GAAP revenue during the reporting period; and remaining contractual revenue expected to be recognized in future periods over the remaining contractual term of that policy. Revenue attributable to periods before the beginning of the applicable reporting period is excluded. A policy that expired or lapsed before the beginning of the reporting period is also excluded. If a policy expires or lapses during the reporting period, Contracted Revenue includes revenue attributable to that policy only through its expiration or lapse date, and no revenue is included for periods thereafter. Standard self-funded plan policies generally have a contractual term of 12 months, while our Three-Year Rate Stabilization Program is designed with a 36-month contractual term. Revenue is recognized under U.S. GAAP on a straight-line basis over the policy term, beginning on the policy’s effective date. Accordingly, Contracted Revenue includes contractual revenue associated with policies that are in force at any time during the applicable reporting period. If a policy expires or lapses during the reporting period, Contracted Revenue includes revenue attributable to that policy only through its expiration or lapse date, and no revenue is included for periods thereafter. Contracted revenue is presented prior to the impact of monthly employers’ enrollment adjustments during the contractual period, including changes in enrolled employees, plan mix, and other factors that may affect premium and fees. Accordingly, actual revenue recognized in future periods may differ from Contracted Revenue. Contracted Revenue is an operating metric and is not a substitute for GAAP revenue.

 

3

 

 

2.Pipeline Revenue represents revenue from self-funded plan policies that are being quoted, are in binding status, or have been contracted subsequent to the end of the reporting period. This metric reflects the entire contractual term of the underlying policies, some of which may not ultimately convert to revenue.

 

3.Adjusted EBITDA is a non-GAAP financial measure. Additional information and reconciliation of Adjusted EBITDA to its most comparable GAAP financial measure is provided in the “Reconciliation of Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA” section of this release.

 

4.Platform Placed Plan Value (“PPPV”) represents the aggregate contractual value of self-funded health plans with stop-loss insurance (self-funded stop-loss plans) placed through the Company’s platform during the fiscal year through the applicable fiscal quarter end, measured over each plan’s full contractual term of typically 12 or 36 months from the plan’s effective date. PPPV reflects the total economic value flowing through the platform, including premium, claim funding, and administrative fees, and is a measure of platform transaction volume rather than an indication of the Company’s own revenue or take rate.

 

Conference Call Details

 

Health In Tech will host a conference call to discuss its financial results for the third quarter of 2026 on November 12, 2026, at 5:00 p.m. (ET). To participate in our live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).

 

A live audio webcast will be available via the Investor Relations page of Health In Tech’s website at https://healthintech.com/. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

 

Non-GAAP Financial Information

 

This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Management uses Adjusted EBITDA to provide investors with additional insight into operational performance and to facilitate comparison with other companies in the industry. Adjusted EBITDA should not be considered an alternative to net income, operating income, or other GAAP measures. A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.

 

4

 

 

Use of Forward-Looking Statements

 

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” “objective” or other words that convey the uncertainty of future events or outcomes. Forward-looking statements made in this press release include, but are not limited to, statements regarding the expected benefits of the Company’s leadership transition; the Company’s strategic focus on accelerating organic growth, commercial execution, expanding adoption of its solutions and strengthening distribution and carrier partnerships; the Company’s intention to evaluate and pursue potential acquisitions, strategic investments, partnerships and other business opportunities; and the Company’s ability to create long-term shareholder value.

 

These forward-looking statements are based on current expectations and beliefs concerning future events and developments and their potential effects on Health In Tech and are subject to numerous known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Health In Tech’s control, that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These factors include, but are not limited to: risks related to the leadership transition, including our ability to successfully integrate new management and retain key personnel; our ability to identify, negotiate, finance, complete and integrate acquisitions or other strategic transactions and investments on favorable terms, or at all; our ability to obtain funding for our operations and to enhance our current systems and expand our service offerings; our ability to regain and maintain compliance with The Nasdaq Stock Market LLC continued listing requirements; the success, cost and timing of our product development activities; our ability to attract and retain key personnel and qualified employees; our ability to attract new customers and to develop new, and enhance existing, products and services; the impact of competition in our industry and innovation by our competitors; risks related to cybersecurity incidents or other network disruptions; risks related to the use of third-party artificial intelligence; our ability to comply with new or modified laws and regulations applicable to our business, including with respect to the insurance services industry and data privacy requirements; our ability to protect our intellectual property rights and maintain and build our brand; the future trading price of our common stock; and other risks and uncertainties described in the “Risk Factors” section of our most recent Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission.

 

Any forward-looking statement made in this press release speaks only as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible for Health In Tech to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release. Except as required by applicable law, Health In Tech does not undertake, and expressly disclaims, any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

 

About Health In Tech

 

Health In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriter (“MGUs”) and third-party administrators (“TPAs”). Health In Tech’s platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.

 

5

 

 

Health In Tech, Inc.

Consolidated Statements of Operations

 

(Unaudited)

 

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Revenues                        
Revenues from underwriting modeling (ICE)   $ 632,613     $ 1,389,604     $ 3,374,074     $ 5,832,164  
Revenues from fees (SMR)     5,954,439       7,100,489       20,041,244       19,986,762  
Total revenues     6,587,052       8,490,093       23,415,318       25,818,926  
                                 
Cost of revenues     3,524,692       3,346,277       11,921,066       9,009,841  
                                 
Gross profit     3,062,360       5,143,816       11,494,252       16,809,085  
                                 
Operating expenses                                
Sales and marketing expenses     2,061,695       962,567       6,569,185       3,279,560  
General and administrative expenses     3,116,656       3,455,996       10,104,489       10,472,224  
Provision for credit losses     5,337,768       (4,089 )     6,074,587       1,901  
Research and development expenses     938,564       235,819       2,734,770       1,356,149  
Total operating expenses     11,454,683       4,650,293       25,483,031       15,109,834  
                                 
Other income (expense):                                
Interest income     64,627       111,699       201,666       305,263  
Interest expense     (20,000 )     —       (20,000 )     —  
Financing transaction costs     (799,630 )     —       (799,630 )     —  
Change in fair value of SEPA derivative liability     (2,235 )     —       (2,235 )     —  
Change in fair value of convertible notes – FVO     (69,502 )     —       (69,502 )     —  
Other income     310       —       122,644       118,399  
Other expense     (35,375 )     (5,000 )     (87,716 )     (5,000 )
Total other income (expense), net     (861,805 )     106,699       (654,773 )     418,662  
(Loss) income before income tax expense     (9,254,128 )     600,222       (14,643,552 )     2,117,913  
Income tax benefit (expense)     2,147,653       (148,046 )     3,437,610       (536,514 )
                                 
Net (loss) income     (7,106,475 )     452,176       (11,205,942 )     1,581,399  
Net loss attributable to noncontrolling interests     (40,062 )     —       (40,224 )     —  
                                 
Net (loss) income attributable to common stockholders   $ (7,066,413 )   $ 452,176     $ (11,165,718 )   $ 1,581,399  
                                 
Net (loss) income per share                                
Basic   $ (0.11 )   $ 0.01     $ (0.18 )   $ 0.03  
Diluted   $ (0.11 )   $ 0.01     $ (0.18 )   $ 0.03  
                                 
Weighted average common shares outstanding:                                
Basic     63,078,291       56,432,407       61,107,984       55,484,860  
Diluted     63,078,291       58,774,334       61,107,984       57,477,873  

 

6

 

 

Reconciliation of Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA

 

(Unaudited)

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Net (loss) income attributable to common stockholders  $(7,066,413)  $452,176   $(11,165,718)  $1,581,399 
Interest income   (44,627)   (111,699)   (181,666)   (305,263)
Amortization expense   278,747    217,981    1,002,534    489,947 
Income tax (benefit) expense   (2,147,653)   148,046    (3,437,610)   536,514 
Stock-based compensation expense, including employer payroll taxes related to stock-based awards   730,041    292,552    2,133,849    1,493,686 
Provision for credit losses on other receivables   2,582,529    —    3,322,302    — 
Provision for credit losses on loans receivable   863,992    —    863,992    — 
Financing transaction costs   799,630    —    799,630    — 
Change in fair value of SEPA derivative liability   2,235    —    2,235    — 
Change in fair value of convertible notes – FVO   69,502    —    69,502    — 
Other non-recurring items   —    —    37,341    — 
Total net adjustments   3,134,396    546,880    4,612,109    2,214,884 
                     
Adjusted EBITDA  $(3,932,017)  $999,056   $(6,553,609)  $3,796,283 

 

7

 

 

Consolidated Balance Sheets

 

(Unaudited)

 

   September 30,   December 31, 
   2026   2025 
Assets        
Current assets        
Cash and cash equivalents  $10,127,237   $7,669,754 
Accounts receivable, net of allowance for credit losses of $1,882,457 and $0 as of September 30, 2026 and December 31, 2025, respectively   3,177,652    756,288 
Loans receivable, net of allowance for credit losses of $863,992 and $0 as of September 30, 2026 and December 31, 2025, respectively   —    815,995 
Other receivables, net of allowance for credit losses of $3,502,581 and $377,587 as of September 30, 2026 and December 31, 2025, respectively   1,669,747    3,467,814 
Deferred offering costs   180,987    170,977 
Prepaid expenses and other current assets   1,933,469    3,280,148 
Total current assets   17,089,092    16,160,976 
Non-current assets          
Software   8,148,785    6,530,894 
Operating lease - right-of-use assets   85,776    139,940 
Long-term prepaid expenses   17,956    258,151 
Deferred tax assets, net   2,691,345    — 
Total non-current assets   10,943,862    6,928,985 
Total assets  $28,032,954   $23,089,961 
           
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable and accrued expenses  $8,348,263   $4,188,811 
SEPA derivative liability   82,629      
Convertible notes payable, at fair value   6,639,108      
Operating lease liabilities - current   83,831    76,195 
Other current liabilities   —    891,598 
Total current liabilities   15,153,831    5,156,604 
Non-current liabilities          
Deferred tax liabilities   —    757,675 
Operating lease liabilities - non-current   —    63,617 
Total non-current liabilities   —    821,292 
Total liabilities   15,153,831    5,977,896 
           
Stockholders’ equity          
Common stock, $0.001 par value; Class A Common stock 150,000,000 shares authorized 53,600,790 and 46,006,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively  $53,601   $46,006 
Common stock, $0.001 par value; Class B Common stock 50,000,000 shares authorized, 11,700,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   11,700    11,700 
Additional paid-in capital   18,727,294    11,834,121 
(Accumulated deficit) retained earnings   (5,945,480)   5,220,238 
Noncontrolling interests   32,008    — 
Total stockholders’ equity   12,879,123    17,112,065 
Total liabilities and stockholders’ equity  $28,032,954   $23,089,961 

 

8

 

 

Consolidated Statements of Cash Flows

 

(Unaudited)

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Cash flows (used in) provided by operating activities:                
Net (loss) income  $(7,106,475)  $452,176   $(11,205,942)  $1,581,399 
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:                    
Bad debt expense (recovery)   1,891,247    (4,089)   1,888,293    1,901 
Amortization expense   278,747    217,981    1,002,534    489,947 
Provision for refund liability   383,854    1,413,345    492,256    2,369,088 
Provision for credit losses on other receivables   2,582,529    —    3,322,302    — 
Provision for credit losses on loans receivable   863,992    —    863,992    — 
Deferred tax (benefit) expense   (2,150,909)   12,680    (3,449,020)   (53,867)
Interest expense (income), net   4,001    (16,003)   (27,997)   (48,001)
Financing transaction costs   799,630    —    799,630    — 
Change in fair value of SEPA derivative liability   2,235    —    2,235    — 
Change in fair value of convertible notes – FVO   69,502    —    69,502    — 
Stock-based compensation expense   728,571    292,552    2,054,453    1,493,686 
Changes in operating assets and liabilities:                    
Accounts receivable   3,477,408    416,592    (4,309,657)   776,574 
Other receivables   (1,116,876)   (16,272)   (1,188,320)   (3,370,854)
Prepaid expenses and other assets   288,402    (335,424)   1,086,441    (897,331)
Operating lease right-of-use assets and liabilities, net   (606)   18    (1,817)   55 
Accounts payable and accrued expenses   (1,636,874)   (224,639)   2,727,926    2,045,258 
Income taxes payable   —    (34,944)   —    (205,253)
Other current liabilities   (403,854)   (1,500,000)   (1,403,854)   (1,500,000)
Net cash (used in) provided by operating activities   (1,045,476)   673,973    (7,277,043)   2,682,602 
                     
Cash flows used in investing activities:                    
Development of software   (842,164)   (744,841)   (1,801,287)   (2,358,213)
Net cash used in investing activities   (842,164)   (744,841)   (1,801,287)   (2,358,213)
                     
Cash flows provided by (used in) financing activities:                    
Proceeds from issuance of common stock in connection with private investment in public equity financing, net of placement agent fees and escrow agent fees   —    —    6,381,000    — 
Proceeds from the issuance of convertible notes payable, net of $350,000 discount   6,650,000    —    6,650,000    — 
Payments of deferred offering costs   (230,027)   (43,685)   (473,635)   (150,024)
Payments of financing costs related to SEPA and convertible notes   (580,000)   —    (580,000)   — 
Contributions from noncontrolling interests   —    —    71,428    — 
Taxes paid related to net share settlement of equity awards   (339,909)   —    (512,980)   — 
Net cash provided by (used in) financing activities   5,500,064    (43,685)   11,535,813    (150,024)
                     
Increase (decrease) in cash and cash equivalents   3,612,424    (114,553)   2,457,483    174,365 
Cash and cash equivalents, beginning of the period   6,514,813    8,138,166    7,669,754    7,849,248 
Cash and cash equivalents, end of the period  $10,127,237   $8,023,613   $10,127,237   $8,023,613 
                     
Supplemental disclosures of cash flow information:                    
Cash paid for interest  $20,000   $—   $20,000   $— 
Cash paid for income taxes  $—   $198,000   $10,035   $823,323 
                     
Summary of noncash investing and financing activities:                    
Accrued deferred offering costs included in accounts payable and accrued expenses  $64,285   $55,827   $64,285   $55,827 
Accrued development of software included in accounts payable and accrued expenses   800,058    401,964    800,058    401,964 
Accrued financing costs in accounts payable and accrued expenses   219,630    —    219,630    — 
Reclassification of deferred offering costs to additional paid-in capital upon private investment in public equity financing   —    —    527,910    — 
Stock-based compensation capitalized for software development   17,978    —    37,432    — 

 

Investor Contact:

 

Health In Tech Investor Relations

ir@healthintech.com

 

9

 

Filing Exhibits & Attachments

4 documents

Keep reading